Provides molecular tests and laboratory and digital care solutions for transplant patients, clinicians and transplant centers.
10-K for FY2025, filed Feb 25, 2026CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver…View ↗
Our commercially available post-transplant testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA, or dd-cfDNA…View ↗
We also offer specialized pharmacy services for transplant patients. The pharmacy helps patients and caregivers access lifesaving…View ↗
Testing services make up 72% of revenue; third-party payers are billed when results are delivered to providers. Laboratory products are sold to end users, distributors and strategic partners when shipped or delivered, while patient and digital solutions earn revenue from software subscriptions and licenses plus medication sales.
10-K for FY2025, filed Feb 25, 2026The healthcare providers that order the tests and on whose behalf the Company provides testing services are generally not responsible for…View ↗
Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition…View ↗
Patient and digital solutions revenue is primarily derived from software as a service, or SaaS, agreements entered into with various…View ↗
Software license agreements typically require advance payments from customers upon the achievement of certain milestones. The Company…View ↗
In addition, the Company derives patient revenue from medication sales. The medication sales revenue is recognized based on the negotiated…View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗$379.8M
10-K for FY2025, filed Feb 25, 2026
$379.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Testing services revenue
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
72%
FY2022: 82%
|
Testing services revenue, FY2025
$274.5M Sources
|
Sold outright |
|
Product revenue
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
13%
FY2022: 9.1%
|
Product revenue, FY2025
$48.4M Sources
|
Sold outright |
|
Patient and digital solutions revenue
Mix
10-K for FY2025, filed Feb 25, 2026 |
15%
FY2022: 9.0%
|
Patient and digital solutions revenue, FY2025
$56.9M Sources
|
Mix |
Healthcare providers order tests for transplant patients, while third-party payers are generally billed; transplant centers are the software customers. CareDx's U.S. regional teams sell into specific transplant centers, while distributors serve centers outside Western Europe; products also go to end users, distributors and strategic partners.
10-K for FY2025, filed Feb 25, 2026AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare and AlloSure Lung patient tests are ordered by healthcare providers. The Company…View ↗
The healthcare providers that order the tests and on whose behalf the Company provides testing services are generally not responsible for…View ↗
Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition…View ↗
Patient and digital solutions revenue is primarily derived from software as a service, or SaaS, agreements entered into with various…View ↗
In the U.S., the organization and delivery of healthcare, including for transplantation, is highly local. To first and foremost empower…View ↗
Outside of the U.S. we similarly have regional structure that includes country managers in Western Europe, and distributors we work with…View ↗
10-K for FY2025, filed Feb 25, 2026
The Company is also subject to credit risk from its accounts receivable, which are primarily derived from revenue earned from AlloSure…View ↗
No. It lost $21.4M in FY2025.
10-Q for Q3 FY2026, filed Oct 29, 2026
$19.3MView ↗
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Jul 30, 2026
Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 MillionView ↗
8-K, filed Jul 7, 2026
On June 30, 2026, CareDx, Inc. (the “Company”) completed the previously announced sale of the shares of CareDx AB, a wholly-owned Swedish…View ↗
Growing. Revenue grew 28% in 4 years, from $296.4M in FY2021 to $379.8M in FY2025, about 6% a year.
Competes with Natera, Eurofins Transplant Genomics, Devyser Diagnostics, Insight Molecular Diagnostics, Thermo Fisher, Omixon, GenDx, BAG, Qiagen, Immucor, and Epic
10-K for FY2025, filed Feb 25, 2026Our competition principally includes clinical reference laboratories and hospital laboratories using existing and routine clinical…View ↗
Loading...